Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2015, vol. 24, nr 4, July-August, p. 555–561

doi: 10.17219/acem/31239

Publication type: editorial article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Large Bowel Genetic Background and Inflammatory Processes in Carcinogenesis – Systematic Review

Łukasz Szylberg1,A,B,C,E, Marlena Janiczek1,B,C,D, Aneta Popiel1,B,C,D, Andrzej Marszałek2,E,F

1 Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland

2 Department of Oncological Pathology, Poznan University of Medical Sciences and Greater Poland Oncology Center, Poland


Colorectal cancer (CRC) has become the third most common cancer in developed countries. Each year more and more people die from CRC. CRC is also one of the most effectively studied topics in recent years. It has been found that the key phenomena in CRC development are genetic and inflammatory processes. Well-known genetic bases for the carcinogenesis of CRC include chromosomal changes characteristic of the chromosomal instability pathway which correlates with specific and well-defined genetic alterations (such as APC, K-RAS, DCC and p53) and genomic instability characteristics for the mutator pathway focused on KRAS and BRAF mutations. Recent studies have highlighted the impact of inflammation in CRC, especially elevated levels of pro-inflammatory cytokines. Among important risk factors of colon carcinogenesis are colorectal polyps, which are currently the subject of intense research. Recent studies have shown that different adenomas are characterized by different pathways of carcinogenesis as well as diverse COX-2 expression in various polyps. Understanding the mechanism of inflammatory processes in CRC parallel to basic genetic alterations might allow for effective and targeted treatment.

Key words

colorectal cancer, inflammation, carcinogenesis, genetic alterations.

References (46)

  1. Spann S, Levin B, Rozen P, Young G: Colorectal cancer: How big is the problem, why prevent it and how might it present? In: Colorectal cancer in clinical practice: prevention, early detection and management. Eds.: Rozen P, Young G, Levin B. Martin Dunitz, London 2002, 1–13.
  2. Stefanius K: Colorectal carcinogenesis via serrated route. Acta Univ Oul D 2011, 1091.
  3. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001, 357, 539–545.
  4. Morrison WB: Inflammation and Cancer: A Comparative View. J Vet Intern Med 2012, 26, 18–31.
  5. Goswami B, Rajappa M, Sharma M: Inflammation: its role and interplay in the development of cancer, with special focus on gynecological malignancies. Int J Gynecol Cancer 2008, 18, 591–599.
  6. Coussens LM, Werb Z: Inflammation and cancer. Nature 2012, 420, 860–867.
  7. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer Statistics. CA Cancer J Clin 2006, 56, 106–130.
  8. Kwong LN, Dove WF: APC and its modifiers in colon cancer. Adv Exp Med Biol 2009, 656, 85–106.
  9. Longacre TA, Fenoglio-Preiser CM: Mixed hyperplastic adenomatous polyps/serrated adenomas. Am J Surg Pathol 1990, 14, 524–537.
  10. Torlakovic EE, Gomez JD, Driman DK: Sessile Serrated Adenoma (SSA) vs. Traditional Serrated Adenoma (TSA). Am J Surg Pathol 2008, 32, 21–44.
  11. Valerie P, Bauer MD, Harry T: Management of Serrated Adenomas and Hyperplastic Polyps. Clin Colon Rectal Surg 2008, 21, 273–279.
  12. Fearon ER, Vogelstein B: A Genetic model for Colorectal Tumorigenesis. Cell 1990, 61, 759–767.
  13. Sandmeier D, Benhattar J, Martine P: Serrated polyps of the large intestine: a molecular study comparing sessile serrated adenomas and hyperplastic polyps. Histopathology 2009, 55, 206–213.
  14. Krasinskas AM: EGFR Signalling in colorectal carcinoma. Patholog Res Int 2011.
  15. Itoh F, Imai K: Genetic diagnosis of colorectal cancer. Hokkaido Iqaku Zasshi 1996, 71, 9–14.
  16. Weisenberger HT: Genome-scale analysis of aberrant Dna methylation in colorectal cancer. Genome Res 2012, 22, 271–282.
  17. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998, 95, 6870–6875.
  18. McLean MH, Murray GI, Stewart KN, Norrie G, Mayer C: The Inflammatory Microenvironment in Colorectal Neoplasia. PLoS ONE 2011, 6, e15366.
  19. Herbeuval JP, Lelievre E, Lambert C, Dy M, Genin C: Recruitment of STAT3 for Production of IL-10 by Colon Carcinoma Cells Induced by Macrophage-Derived IL-6. J Immunol 2004, 172, 4630–4636.
  20. Becker C, Fantini MC, Wirtz S: IL-6 Signaling Promotes Tumor Growth in Colorectal Cancer. Cell Cycle 2005, 4, 217–220.
  21. Stanilov N, Stankova N, Miteva L, Jovchev J, Deliyski T, Stanilova S: Role of IL-12P40 and IL-10 in progression of colorectal cancer. TJS 2010, 8, 132–136.
  22. Stanilov N, Miteva L, Deliysky T, Jovchev J, Stanilova S: Advanced Colorectal Cancer Is Associated With Enhanced IL-23 and IL-10 Serum Levels. Labmedicine 2010, 41, 159–163.
  23. Cacev T, Radosevic S, Krizanac S, Kapitanović S: Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis 2008, 29, 1572–1580.
  24. O’Hara R J, Greenman J, MacDonald AW, Gaskell KM, Topping KP, Duthie GS, Kerin MJ, Lee PW, Monson JR: Advanced colorectal cancer is associated with impaired interleukin-12 and enhanced interleukin-10 production. Clin Cancer Res 1998, 4, 1943–1948.
  25. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313, 1960–1964.
  26. Kanai T, Watanabe M, Hayashi A, Nakazawa A, Yajima T, Okazawa A, Yamazaki M, Ishii H, Hibi T: Regulatory effect of interleukin-4 and interleukin-13 on colon cancer cell adhesion. Br J Cancer 2000, 82, 1717–1723.
  27. Wiiliam CS, Mann M, Dubois RN: The role of cycloxygenases in inflammation, cancer and development. Oncogene 1999, 18, 7906–7916.
  28. Legan M: Cyclooxygenase-2, p53 and glucose transporter-1 as predictors of malignancy in the development of gallbladder carcinomas. Bosn J Basic Med Sci 2010, 10, 192–196.
  29. Gustafsson Asting A, Caren H, Andersson M, Lönnroth C, Lagerstedt K, Lundholm K: COX-2 gene expression in colon cancer tissue related to regulating factors and promotor methylation status. BMC Cancer 2011, 11, 238.
  30. Balbinotti RA, Ribeiro U, Saka P, Safatle-Ribeiro AV, Balbinotti SS, Scapulatempo C, Alves VA, Corbett CE, Carrilho FJ: hMLH1, hMSH2 and Cyclooxygenase-2 (Cox-2) in Sporadic Colorectal Polyps. Anticancer Res 2007, 27, 4465–4472.
  31. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Glickman JN, Chan AT, Kirkner GJ, Mino-Kenudson M, Fuchs CS, Ogino S: Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma. BMC Cancer 2008, 8, 33.
  32. Menter DG, Schilsky RL, DuBois RN: Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 2010, 16, 1384–1390.
  33. Romagnolo DF, Papoutsis AJ, Selmin O: Nutritional targeting of cyclooxygenase-2 for colon cancer prevention. Inflamm Allergy Drug Targets 2010, 9, 181–191.
  34. Pelzer O, Kielan W: Risk analysis for the surgical treatment of colorectal cancer in elderly patients undergoing scheduled and urgent interventions. Pol Przegl Chir 2014, 86, 61–67.
  35. Rayburn ER, Ezell SJ, Zhang R: Anti-Inflammatory Agents for Cancer Therapy. Mol Cell Pharmacol 2009, 1, 29–43.
  36. Peura DA, Wilcox CM: Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett’s esophagus. Postgrad Med 2014, 126, 87–96.
  37. Sostres C, Lanas A: Gastrointestinal effects of aspirin. Nat Rev Gastroenterol Hepatol 2011, 8, 385–394.
  38. Lanas A: Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice. Expert Opin Drug Saf 2011, 10, 45–54.
  39. Kim SH, Margalit O, Katoh H, Wang D, Wu H, Xia D, Holla VR, Yang P, DuBois RN: CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models. Invest New Drugs 2014, PMID: 25085205.
  40. Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, Maguire C, Hind D, Tappenden P: Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2010, 14, 1–206.
  41. Lin LL, Hahn SM: Combined modality therapy in the elderly population. Curr Treat Options Oncol 2009, 10, 195–204.
  42. U.S. Census Bureau: National Population Projections. Percent Distribution of the Projected Population by Selected Age Groups and Sex for the United States: 2010 to 2050., accessed 2009.
  43. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics 2010. CA Cancer J Clin 2010, 60, 277–300.
  44. Foster JA, Salinas GD, Mansell D, Williamson JC, Casebeer LL: How Does Older Age Influence Oncologists’ Cancer Management? The Oncologist 2010, 15, 584–592.
  45. Dotan E, Browner I, Hurria A, Denlinger C: Challenges in the Management of Older Patients with Colon Cancer. J Natl Compr Canc Netw 2012, 10, 213–225.
  46. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, Housman MG, Escarce JJ: Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003, 21, 1383–1389.